Cell therapy has achieved a new breakthrough: iPSC (induced pluripotent stem cell) technology has entered the clinical application stage in Shanghai. This technology promises new treatment pathways for difficult diseases such as Parkinson's disease, macular degeneration and diabetes, attracting widespread attention from the medical community and patients.
What is iPSC technology
iPSCs are cells obtained by reprogramming adult cells into a pluripotent state similar to embryonic stem cells, with the ability to differentiate into various cell types of the human body. Compared with embryonic stem cells, iPSCs avoid ethical controversies and can be autologous, reducing the risk of immune rejection.
Clinical application progress
In Shanghai, iPSC-derived cell therapies have been studied in multiple fields, including dopamine neurons differentiated from iPSCs for Parkinson's disease and retinal pigment epithelial cells for macular degeneration. Early clinical data are encouraging, with long-term safety and efficacy still under continuous follow-up.
Significance for international patients
For patients with difficult diseases lacking effective treatments in their home countries, iPSC-related clinical programs offer new hope. International patients can follow clinical trial recruitment information at relevant institutions in Shanghai and evaluate eligibility through formal channels.
MedBridge services
MedBridge can help international patients learn about the progress and recruitment of iPSC-related clinical programs in Shanghai, providing medical record evaluation, expert consultation and arrangements for treatment in Shanghai.